Is Ilmn a good stock to buy?

(NASDAQ: ILMN) Illumina’s forecast annual earnings growth rate of 9.4% is not forecast to beat the US Diagnostics & Research industry’s average forecast earnings growth rate of 13.87%, and while it is not forecast to beat the US market’s average forecast earnings growth rate of 15.92%.

Table of Contents

Is Ilmn overvalued?

Illumina retains a regular Real Value of $250.6 per share. The prevalent price of the firm is $189.21. At this time, the firm appears to be undervalued….6.91.

Low	Projected EPS	High
5.53	5.66	5.77

Is Illumina a buy or sell or hold?

Illumina has received a consensus rating of Hold. The company’s average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.

When did Ilmn go public?

July 28, 2000
At what price? Illumina went public on July 28, 2000 at a price of $16.00, or $8.00 on a split-adjusted basis.

Will CRSP stock go up?

Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 108.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +29.55% increase from the last price of 83.75.

Is Illumina a buy Zacks?

Zacks’ proprietary data indicates that Illumina, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ILMN shares relative to the market in the next few months.

Who are illuminas customers?

Customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.

Where will CRSP stock be in 5 years?

CRISPR Therapeutics (CRSP 5.57%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025. That’s an improvement of more than 191,000% in five years.

Is CRSP a Buy Sell or Hold?

CRISPR Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.63, and is based on 10 buy ratings, 6 hold ratings, and no sell ratings.

What are Illumina’s values?

Illumina Values

We are open.
Innovation is in our DNA.
We are relentless in the creation of great products.
We move fast and embrace change.
We collaborate deeply.

Is Illumina a great company?

87% of employees at Illumina say it is a great place to work compared to 57% of employees at a typical U.S.-based company. Source: Great Place to Work® 2021 Global Employee Engagement Study.

Who are Illumina’s customers?

What are analysts’ price targets for Illumina Inc (ilmn)?

The 17 analysts offering 12-month price forecasts for Illumina Inc have a median target of 400.00, with a high estimate of 555.00 and a low estimate of 295.00. The median estimate represents a +32.76% increase from the last price of 301.30.

How does Illumina (ilmn) stock rank on Wall Street?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Illumina stock is Hold based on the current 1 sell rating, 7 hold ratings and 4 buy ratings for ILMN. The average twelve-month price target for Illumina is $441.17 with a high price target of $570.00 and a low price target of $340.00.

Where can I buy ilmn stock?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.